Posted by Michael Wonder on 19 Oct 2025
Azurity Pharmaceuticals announces the FDA approval of Ferabright (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging of the brain
17 October 2025 - Azurity Pharmaceuticals announced today that the US FDA has approved Ferabright (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging of the brain in adults with known or suspected malignant neoplasms in the brain to visualise lesions with a disrupted blood-brain barrier.
In a clinical trial, Ferabright-enhanced MRI significantly improved visualisation of primary and secondary brain neoplasms compared with pre-contrast imaging.
